By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences posted revenues of $10.6 million in the second quarter, including its first product revenues from the sale of its PacBio RS third-generation sequencing platform, the company reported after the close of the market on Thursday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.